alantolactone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Cui, R; Dai, X; Huang, X; Liang, G; Rajamanickam, V; Wang, C; Wang, O; Yin, C; Zhang, X; Zhao, C; Zhou, Q; Zhu, W; Zou, P | 1 |
1 other study(ies) available for alantolactone and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lactones; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Sesquiterpenes, Eudesmane; Thioredoxin Reductase 1; Thioredoxin-Disulfide Reductase; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |